Subscribe
istock-693373540_natali_mis
Natali_Mis / iStockphoto.com
7 March 2018Europe

EPO grants second CRISPR patent to ERS Genomics

The European Patent Office (EPO) has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
USPTO grants another CRISPR patent to Charpentier
12 March 2019   The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
USPTO grants Charpentier-founded company first CRISPR patent
20 June 2018   The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
USPTO grants another CRISPR patent to Charpentier
12 March 2019   The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
USPTO grants Charpentier-founded company first CRISPR patent
20 June 2018   The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.

More on this story

Americas
USPTO grants another CRISPR patent to Charpentier
12 March 2019   The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
USPTO grants Charpentier-founded company first CRISPR patent
20 June 2018   The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes